Brown Rudnick acted on behalf of the nomad/broker, N+1 Singer, Realm Therapeutics PLC announced on 21 September 2017 to raise £19.3 million on AIM. The Placing comprises of a UK Placing and a US Placing. It is expected that the Placing Shares will be admitted to trading on AIM on or around 10 October.

Realm Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapies with potential application for the treatment of diseases in a number of therapeutic areas, and with an initial focus in dermatology and ophthalmology.

The Brown Rudnick team included London Corporate partner Sophie McGrath, Boston Corporate partner Jason McCaffrey and London Associate Peter Wozny.

To learn more about this deal please read the following press release: